… The primary objective of the study is to determine the superiority of dapagliflozin vs. … heart
failure events (hospitalization for heart failure or urgent heart failure visit) or cardiovascular …

… Participants were randomized to 10 mg dapagliflozin or … of cardiovascular death or worsening
heart failure (heart failure … the DELIVER study who had HFimpEF, dapagliflozin compared …

… heart failure with a focus on dapagliflozin and the ongoing DELIVER trial evaluating dapagliflozin
… This article is based on previously conducted studies and does not contain any studies …

… Patients With PReserved Ejection Fraction Heart Failure), 16 we … of dapagliflozin on SBP,
evaluate the effect of dapagliflozin on … Endpoints studied in this analysis include time to first …

… et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly
reduced or … The strengths of our study include the relatively large number of patients with …

… the primary end point of cardiovascular death or worsening heart failure, with first … study,
dapagliflozin led to early and sustained reductions in clinical events in patients with heart failure …

… In our study, whereas greater frailty was associated with higher rates of adverse events
and discontinuation of randomized treatment, neither was more common in the …

… et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly
reduced or … The primary outcome for each study was a composite of worsening HF events (…

… of this study. BMI, body mass index; CV, cardiovascular; DELIVER, Dapagliflozin Evaluation
to … Fraction Heart Failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, …

… The purpose of this study was to investigate clinical outcomes and response to dapagliflozin
in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF) …